产品
编 号：F165499
分子式：C22H36N2O5S
分子量：440.6
分子式：C22H36N2O5S
分子量：440.6
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 144494-65-5
产品详情
生物活性：
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
体内研究：
Tirofiban (60 μg/kg；静脉注射；一次) 显示出通过增加 HR、LVESP、dp/dtmax 和降低 LVEDP 来增加收缩力、心室顺应性和改善心脏功能的活性。 Tirofiban (60 μg/kg；静脉注射；一次) 增强 eNOS 活性，降低 iNOS 活性并减少 AMI 后再灌注后的无复流面积。 Tirofiban (50 μg/per；irrigate；单剂量) 在挤压模型中显示出抗凝作用，微血管吻合后 24 小时通畅率为 59%。Animal Model:Male Sprague-Dawley rats (10 to 15-week-age; 270-330 g).
Dosage:60 μg/kg
Administration:Intravenous injection; once.
Result:Increased contraction force, ventricular compliance, and improved heart function.Reduced the size of no-reflow and infarct.
Animal Model:Sprague-Dawley rats (350-400 g; crush injury model)
Dosage:50 μg/per (50 μg/mL, 1 mL for each)
Administration:Irrigate 1 mL within the vessel lumen (before placement of the last suture); once.
Result:Showed anticoagulant effect with patency rates of 59%.
体外研究：
Tirofiban (0.25、1、3 μg/mL；72 小时) 增加 HAEC 细胞的增殖。 Tirofiban (24 小时) 在 18 小时内关闭 HUVEC 迁移的划痕。 Tirofiban (0.25，1 μg/mL；1小时) 在30分钟后诱导产生VEGF，刺激内皮细胞增殖。
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
体内研究：
Tirofiban (60 μg/kg；静脉注射；一次) 显示出通过增加 HR、LVESP、dp/dtmax 和降低 LVEDP 来增加收缩力、心室顺应性和改善心脏功能的活性。 Tirofiban (60 μg/kg；静脉注射；一次) 增强 eNOS 活性，降低 iNOS 活性并减少 AMI 后再灌注后的无复流面积。 Tirofiban (50 μg/per；irrigate；单剂量) 在挤压模型中显示出抗凝作用，微血管吻合后 24 小时通畅率为 59%。Animal Model:Male Sprague-Dawley rats (10 to 15-week-age; 270-330 g).
Dosage:60 μg/kg
Administration:Intravenous injection; once.
Result:Increased contraction force, ventricular compliance, and improved heart function.Reduced the size of no-reflow and infarct.
Animal Model:Sprague-Dawley rats (350-400 g; crush injury model)
Dosage:50 μg/per (50 μg/mL, 1 mL for each)
Administration:Irrigate 1 mL within the vessel lumen (before placement of the last suture); once.
Result:Showed anticoagulant effect with patency rates of 59%.
体外研究：
Tirofiban (0.25、1、3 μg/mL；72 小时) 增加 HAEC 细胞的增殖。 Tirofiban (24 小时) 在 18 小时内关闭 HUVEC 迁移的划痕。 Tirofiban (0.25，1 μg/mL；1小时) 在30分钟后诱导产生VEGF，刺激内皮细胞增殖。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备